|
1
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, Function, and role in cancer. Curr Genomics.
11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Billeter AT, Druen D, Kanaan ZM and Polk
HC Jr: MicroRNAs: New helpers for surgeons? Surgery. 151:1–5. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Croce CM: Oncogenes and cancer. N Engl J
Med. 358:502–511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meltzer PS: Cancer genomics: Small RNAs
with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Humphries B and Yang C: The microRNA-200
family: Small molecules with novel roles in cancer development,
progression and therapy. Oncotarget. 6:6472–6498. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paterson EL, Kazenwadel J, Bert AG,
Khew-Goodall Y, Ruszkiewicz A and Goodall GJ: Down-regulation of
the miRNA-200 family at the invasive front of colorectal cancers
with degraded basement membrane indicates EMT is involved in cancer
progression. Neoplasia. 15:180–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar S, Nag A and Mandal CC: A
comprehensive review on miR-200c, A promising cancer biomarker with
therapeutic potential. Curr Drug Targets. 16:1381–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Armaghany T, Wilson JD, Chu Q and Mills G:
Genetic alterations in colorectal cancer. Gastrointest Cancer Res.
5:19–27. 2012.PubMed/NCBI
|
|
12
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jancik S, Drabek J, Radzioch D and Hajduch
M: Clinical relevance of KRAS in human cancers. J Biomed
Biotechnol. 2010:1509602010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brand TM and Wheeler DL: KRAS mutant
colorectal tumors: Past and present. Small GTPases. 3:34–39. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Wang Q, Hu W and Evers BM:
Regulation of phorbol ester-mediated TRAF1 induction in human colon
cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway.
Oncogene. 23:1885–1895. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vos MD, Ellis CA, Elam C, Ulku AS, Taylor
BJ and Clark GJ: RASSF2 is a novel K-Ras-specific effector and
potential tumor suppressor. J Biol Chem. 278:28045–28051. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akino K, Toyota M, Suzuki H, Mita H,
Sasaki Y, Ohe-Toyota M, Issa JP, Hinoda Y, Imai K and Tokino T: The
Ras effector RASSF2 is a novel tumor-suppressor gene in human
colorectal cancer. Gastroenterology. 129:156–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carter JV, Roberts HL, Pan J, Rice JD,
Burton JF, Galbraith NJ, Eichenberger MR, Jorden J, Deveaux P,
Farmer R, et al: A highly predictive model for diagnosis of
colorectal neoplasma using plasma MicroRNA: Improving Specificity
and Sensitivity. Ann Surg. 264:575–584. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hyun S, Lee JH, Jin H, Nam J, Namkoong B,
Lee G, Chung J and Kim VN: Conserved MicroRNA miR-8/miR-200 and its
target USH/FOG2 control growth by regulating PI3K. Cell.
139:1096–1108. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berg KCG, Eide PW, Eilertsen IA,
Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA,
Eknæs M, Lind GE, et al: Multi-omics of 34 colorectal cancer cell
lines-a resource for biomedical studies. Mol Cancer. 16:1162017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhong X, Zheng L, Shen J, Zhang D, Xiong
M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, et al: Suppression
of MicroRNA 200 family expression by oncogenic KRAS activation
promotes cell survival and epithelial-mesenchymal transition in
KRAS-driven cancer. Mol Cell Biol. 36:2742–2754. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kopp F, Wagner E and Roidl A: The
proto-oncogene KRAS is targeted by miR-200c. Oncotarget. 5:185–195.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
O'Brien SJ, Carter JV, Burton JF, Oxford
BG, Schmidt MN, Hallion JC and Galandiuk S: The role of the miR-200
family in epithelial-mesenchymal transition in colorectal cancer: A
systematic review. Int J Cancer. 142:2501–2511. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bojmar L, Karlsson E, Ellegard S, Olsson
H, Björnsson B, Hallböök O, Larsson M, Stål O and Sandström P: The
role of microRNA-200 in progression of human colorectal and breast
cancer. PLoS One. 8:e848152013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Troppmair J, Bruder JT, Munoz H, Lloyd PA,
Kyriakis J, Banerjee P, Avruch J and Rapp UR: Mitogen-activated
protein kinase/extracellular signal-regulated protein kinase
activation by oncogenes, serum and
12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary
for transformation. J Biol Chem. 269:7030–7035. 1994.PubMed/NCBI
|
|
30
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schubbert S, Bollag G, Lyubynska N, Nguyen
H, Kratz CP, Zenker M, Niemeyer CM, Molven A and Shannon K:
Biochemical and functional characterization of germ line KRAS
mutations. Mol Cell Biol. 27:7765–7770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tan C and Du X: KRAS mutation testing in
metastatic colorectal cancer. World J Gastroenterol. 18:5171–5180.
2012.PubMed/NCBI
|
|
33
|
Perdigao-Henriques R, Petrocca F,
Altschuler G, Thomas MP, Le MT, Tan SM, Hide W and Lieberman J:
miR-200 promotes the mesenchymal to epithelial transition by
suppressing multiple members of the Zeb2 and Snail1 transcriptional
repressor complexes. Oncogene. 35:158–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons
DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, et
al: miR-200 Inhibits lung adenocarcinoma cell invasion and
metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnston SR: Farnesyl transferase
inhibitors: A novel targeted therapy for cancer. Lancet Oncol.
2:18–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Diaz T, Tejero R, Moreno I, Ferrer G,
Cordeiro A, Artells R, Navarro A, Hernandez R, Tapia G and Monzo M:
Role of miR-200 family members in survival of colorectal cancer
patients treated with fluoropyrimidines. J Surg Oncol. 109:676–683.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bhangu A, Wood G, Brown G, Darzi A, Tekkis
P and Goldin R: The role of epithelial mesenchymal transition and
resistance to neoadjuvant therapy in locally advanced rectal
cancer. Colorectal Dis. 16:O133–O143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pichler M, Ress AL, Winter E, Stiegelbauer
V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW,
Kiesslich T, et al: MiR-200a regulates epithelial to mesenchymal
transition-related gene expression and determines prognosis in
colorectal cancer patients. Br J Cancer. 110:1614–1621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elson-Schwab I, Lorentzen A and Marshall
CJ: MicroRNA-200 family members differentially regulate
morphological plasticity and mode of melanoma cell invasion. PLoS
One. 5(pii): e131762010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A,
Petrocca F, Martinvalet D, Song E, Lim B and Lieberman J: miR-200
enhances mouse breast cancer cell colonization to form distant
metastases. PLoS One. 4:e71812009. View Article : Google Scholar : PubMed/NCBI
|
